Diagnostic challenge of desmoplastic melanoma

Olga Andreevscaia,1 Ivan Theate,2 Cathy Goossens,1 Olivier Vanhootegeh1
1Department of Dermatology, St. Elisabeth Hospital, Namur; 2Department of Pathology, Institut de Pathologie et de Génétique, Gosselies, Belgium

Abstract

Desmoplastic melanoma (DM) is a rare variant of spindle-cell malignant melanoma. DM is easily misdiagnosed at an early stage because it can be confused with benign entities. Histological analysis, including careful attention to the presence of atypical spindle cells, as well as to lymphocytic aggregates in an abundant fibrotic stroma in the dermis, provides clues for diagnosis. The adjunction of an immunohistochemical panel, and particularly testing for S-100 protein, is needed for the final diagnosis.

Introduction

Desmoplastic melanoma (DM) is an uncommon variant of melanoma that was first described by Conley et al.1 DM typically presents as a non-pigmented lesion and is occasionally associated with an adjacent in situ manifestation of malignant melanoma. DM accounts for less than 4% of primary cutaneous melanomas,1–3 representing an overall incidence rate of 2.0 per million, with an annual percentage increase of 4.6%. There is a male predilection, with a male/female ratio of nearly 2:1. The majority of these types of lesions are diagnosed in the age range of 59–71 years. The head and neck are the primary sites of DM predilection for both sexes.4

Case Report

A 73-year-old man presented with an asymptomatic, achromatic mandibular plaque that he had borne for several years. Over the preceding 5 months, the lesion had increased in size. On physical examination, an indurated plaque of 3.5 cm in diameter was observed (Figure 1). The clinical differential diagnoses included an infundibular cyst, dermatofibroma, dermatofibrosarcoma, a parotid tumor, pilomatrixoma and a scar. Histopathological examination revealed non-pigmented spindle-shaped malignant melanocytes interspersed within a prominent desmoplastic stroma in the dermis (desmoplasia was more than 90%). Several lymphoid aggregates were observed at the periphery. The tumor cells had minimal atypia (Figure 2). Breslow’s thickness was 4 mm, and malignant cells had invaded the reticular dermis (Clark’s level IV). Immunohistochemistry revealed tumor cells that were positive for S-100 protein but negative for melan-A or HMB45. No junctional activity or neurotropism was found (Figure 3). Pure DM (pDM) without neurotropism was diagnosed, and the patient was referred to the department of plastic surgery for a wide excision and, due to the high tumor thickness, for sentinel lymph node (SLN) biopsy, which showed no residual tumor and no lymph node involvement. Magnetic resonance imaging revealed no distant metastasis. The clinical stage was scored as IIA.

Discussion

Desmoplasia refers to the growth of dense connective tissue of the stroma. This growth is characterized by low cellularity within a hyalinized or sclerotic stroma and by disorganized blood vessel infiltration. The diagnosis of DM is difficult because of variability in clinical appearance and a frequent absence of pigmentation. DM can mimic a scar or different tumors, such as an infundibular cyst, pilomatrixoma, or dermatofibrosarcoma, as in our case. Dermoecoscopy is a useful aid during the evaluation of DM. The most common dermoscopic features found in DMs include atypical vascular structures, peppering, and occasional atypical globules and regression structures, such as scar-like areas and atypical crystalline structures.5,6 Histologically, most DMs are fibrosing spindle-cell tumors. This type of tumor is characterized by spindle-shaped malignant melanocytes within an abundant collagenous stroma. Lymphocytic aggregates often surround or infiltrate the tumors. The cytological atypia of DM is relatively variable, ranging from a fairly bland spindle form to marked nuclear pleomorphism. An in situ melanoma component is observed in more than 80% of DM cases. The histopathological diagnosis of pDM is occasionally difficult for pathologists because of a frequent absence of pigmentation, the relative rarity of tumor cells and the absence of a junctional component.

The application of immunohistochemistry, and particularly analysis of S-100, SOX-10 and p75, is mandatory for the diagnosis of melanoma. The distinction between paucicellular pDM and scarring may be straightforward. Immature scars may also express S-100, and pDM is mostly negative for other melanocytic markers, such as HMB45, microphthalmia transcription factor (MITF) or melan-A. Morphologic clues include nuclear atypia, poor circumscription of the lesion, lymphoid collections and strong positivity for S-100. Moreover, a diagnostic algorithm recently proposed by Weissenger et al. considers the immunophenotype of the tumor and the amount of collagen in the tumor in order to distinguish DM from spindle-cell melanoma.7

According to the different proportions of desmoplastic components in the tumors, DMs can be subdivided into pDM with more than 90% desmoplasia and mixed DM (mDM) with less than 90% desmoplasia.8 The histological categorization is clinically relevant because pDM appears to have a distinct clinical biology (i.e., an increased tumor thickness, an advanced Clark level, a low incidence of primary tumor ulceration, a low incidence of SLN positivity, and tumor recurrence) compared with mDM and non-DM melanoma subtypes.8

The presence of neurotropism within melanoma, increases the risk of local recurrence.1 The primary treatment is complete surgical excision. If nerve involvement is docu-
mented, wide excision is preferable. Due to the decreased potential for metastasis to regional lymph nodes (reported rates of 0-15%), an SLN biopsy is still controversial. For the current case, we preferred to perform SLN biopsy. Pawlik et al. proposed that the treatment approach for mDM should be similar to that for other melanomas, whereas an SLN biopsy may not be warranted in pDM because of the low incidence of SLN metastasis. This clinical evolution suggests that the behavior of pDM is more similar to that of soft-tissue sarcoma, which has also a low predilection for regional lymph node metastasis.

Conclusions

In conclusion, DM is a rare variant of spindle-cell malignant melanoma. DM is easily misdiagnosed at an early stage because it can be confused with benign entities. A lesion
biopsy and careful attention to the presence of spindle cells associated with lymphocytic aggregates in an abundant fibrotic stroma in the dermis may provide clues for diagnosis.

References

1. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971;28:914-36.
2. Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol 2005;12:92-102.
3. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998;83:1128-35.
4. Feng Z, Wu X, Chen V, et al. Incidence and survival of desmoplastic melanoma in the United States, 1992-2007. J Cutan Pathol 2011;38:616-24.
5. Jaimes N, Chen L, Dusza SW, et al. Clinical and dermoscopic characteristics of desmoplastic melanomas. JAMA Dermatol 2013;22:48.
6. Debarbieux S, Ronger-Salve S, Dalle S, et al. Dermoscopy of desmoplastic melanoma: report of six cases. Br J Dermatol 2008;159:360-3.
7. Weissinger SE, Keil P, Silvers DN, et al. A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma. Mod Pathol 2014;27:524-34.
8. Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 2006;106:900.
9. Jaroszewski DE, Pockaj BA, DiCaudo DJ, Bite U. The clinical behavior of desmoplastic melanoma. Am J Surg 2001;182:590-5.
10. Gyorki DE, Busam K, Panageas K, et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol 2003;10:403-7.
11. Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 1987;60:1800-8.
12. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993;217:72-7.